|
Headlines:
|
 |
Back to Oncology Conference Calendar
Bortezomib (Velcade) improves survival in relapsed multiple myeloma
June 5-8, 2004. New Orleans, LA.
|
|
|
The ASCO (American Society Of Clinical Oncology) Annual Meeting is the
premier oncology educational and scientific event.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In a phase III trial Bortezomib, a proteosome
inhibitor, was compared to high dose dexamethasone in patients with
relapsed, refractory multiple myeloma.
The study included 669 patients and results showed a 30%
reduction in mortality in the first year. Median time to disease
progression was 5.6 months versus 3.6 months in the dexamethasone arm.
Bortezomib gained FDA approval in February, 2003.
Legal Disclaimer
The materials presented here were prepared by independent authors
under the editorial supervision of The Doctors Lounge, and do not represent a
publication of the American Society of Clinical Oncology. These
materials and the related activity are not sanctioned by the American
Society of Clinical Oncology or the commercial supporter of the
conference, and do not constitute an official part of that conference.
The material presented here does not reflect the views of The Doctors
Lounge or
the companies providing unrestricted educational grants. These materials
may discuss uses and dosages for therapeutic products that have not been
approved by the United States Food and Drug Administration. A qualified
health care professional should be consulted before using any
therapeutic product discussed. All readers or continuing education
participants should verify all information and data before treating
patients or employing any therapies described in this educational
activity.
Copyright © 2004 The Doctors Lounge.

|
|
|
|
Are you a doctor or a nurse?
Do you want to join the Doctors Lounge online medical community?
Participate in editorial activities (publish, peer review, edit) and
give a helping hand to the largest online community of patients.
Click on the link below to see the requirements:
Doctors Lounge Membership
Application |
|
|